Oxford spinout uses nanoparticles to target tough cancers
- 1 September 2015
A new Oxford spinout is planning to commercialise titania nanoparticles capable of generating cancer-killing free oxygen radicals in tandem with radiotherapy to treat patients with malignant tumours.
Xerion Healthcare, set up with the help of Isis Innovation, the University’s technology commercialisation company, has raised £1.5 million from London’s New Wave Ventures and Parkwalk Advisors to continue development and pre-clinical testing of its therapies. Xerion’s technology is based on over seven years of research by Dr Helen Townley at Oxford’s Department of Engineering Sciences.
Read more (ISIS Innovation website)